TVGN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Tevogen Bio Holdings Inc (TVGN) is not a strong buy for a beginner, long-term investor at this time. The stock shows technical weakness, lacks positive trading signals, and has negative sentiment from analysts. While there are some potential catalysts, such as the planned CRO acquisition, the company's financial performance and recent reverse stock split create significant concerns. A hold strategy is recommended until more favorable conditions arise.
The stock is currently oversold with an RSI of 18.437, indicating potential for a short-term bounce. However, the moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its support level of 4.74, suggesting weak momentum. The MACD histogram is positive at 0.0723, but overall trends remain bearish.
Tevogen's planned CRO acquisition, expected to generate $20 million in annual revenue, could enhance its growth in oncology and rare diseases. Additionally, the company has regained compliance with NASDAQ's minimum bid price requirement, avoiding delisting.
The recent 50:1 reverse stock split is perceived negatively by the market and adds near-term trading pressure. Analysts have downgraded the stock to Hold, citing weaker capital markets positioning. The company's financials show no revenue growth and a net income loss, reflecting poor performance.
In Q3 2025, Tevogen reported no revenue growth (0% YoY), a net income loss of -$5,862,428 (-0.80% YoY), and an EPS of -0.03 (0% YoY). Gross margin remains at 0%, indicating no profitability.
D. Boral Capital downgraded Tevogen to Hold from Buy, citing the negative impact of the reverse stock split and weaker capital markets position. No price target was provided.
